Meeting
2019 Genitourinary Cancers Symposium
Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.
Authors
Laurence Albiges
Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France, Villejuif, France
Laurence Albiges , Sylvie Negrier , Cécile Dalban , Christine Chevreau , Gwenaelle Gravis , Stephane Oudard , Brigitte Laguerre , Philippe Barthelemy , Delphine Borchiellini , Marine Gross-Goupil , Lionnel Geoffrois , Frederic Rolland , Antoine Thiery-Vuillemin , Florence Joly , Sylvain Ladoire , Florence Tantot , Bernard Escudier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT03013335
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 542)
DOI
10.1200/JCO.2019.37.7_suppl.542
Abstract #
542
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study.
First Author: Laurence Albiges
Poster
2018 ASCO Annual Meeting
Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.
First Author: Martin Boegemann
Poster
2017 ASCO Annual Meeting
Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study.
First Author: Bernard J. Escudier
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.
First Author: Kunihiro Fushiki